Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension

Hypertension

Volumn 67, Issue 4, 2016, Pages 701-709

  Wallbach, Manuel ^a   Lehnig, Luca Yves ^a   Schroer, Charlotte ^a   Lüders, Stephan ^b   Böhning, Enrico ^a   Müller, Gerhard A ^a   Wachter, Rolf ^a   Koziolek, Michael J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b ST JOSEFS HOSPITAL   (Germany)

Author keywords

ambulatory blood pressure monitoring; baroreflex activation; blood pressure; carotid sinus; resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BAROREFLEX ACTIVATION THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; RESISTANT HYPERTENSION; RISK REDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; AGED; ANALYSIS OF VARIANCE; CAROTID SINUS; CONFIDENCE INTERVAL; DEVICES; DRUG RESISTANCE; ELECTRODE IMPLANT; ELECTROSTIMULATION; EQUIPMENT DESIGN; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSIOLOGY; PRESSORECEPTOR REFLEX; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE MONITORING, AMBULATORY; CAROTID SINUS; CONFIDENCE INTERVALS; DRUG RESISTANCE; ELECTRIC STIMULATION; ELECTRODES, IMPLANTED; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84960808894     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06717     Document Type: Article

References (44)

1. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA., Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011 58 765 773. doi: 10.1016/j.jacc.2011.06.008.
2. Scheffers IJ, Kroon AA, Schmidli J, Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010 56 1254 1258. doi: 10.1016/j.jacc.2010.03.089.
3. Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC., Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail 2015 17 1066 1074. doi: 10.1002/ejhf.299.
4. Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G., Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014 16 977 983. doi: 10.1002/ejhf.138.
5. Kougias P, Weakley SM, Yao Q, Lin PH, Chen C., Arterial baroreceptors in the management of systemic hypertension. Med Sci Monit 2010 16 RA1 RA8
6. Tordoir JH, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, Herold U, Irwin E, Kroon AA, de Leeuw P, Peters TK, Kieval R, Cody R., An implantable carotid sinus baroreflex activating system: surgical technique and short-Term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007 33 414 421. doi: 10.1016/j.ejvs.2006.11.025.
7. Thai NN., Anesthetic management for implantation of a treatment device: the Rheos Baroreflex Hypertensive Therapy System. AANA J 2012 80 18 24
8. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J., Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010 55 619 626. doi: 10.1161/HYPERTENSIONAHA.109.140665.
9. Schmidli J, von Allmen RS, Mohaupt MG., Electrical carotid baroreceptor stimulation. Wien Med Wochenschr 2014 164 508 514. doi: 10.1007/s10354-014-0329-2.
10. Alnima T, Schutten M, de Leeuw PW, Kroon AA., 8B.09: Right-sided dominance of carotid baroreceptor reflexes in patients with resistant hypertension. J Hypertens 2015 33 suppl 1 e109. doi: 10.1097/01.hjh.0000467645.92988.aa.
11. de Leeuw PW, Alnima T, Lovett E, Sica D, Bisognano J, Haller H, Kroon AA., Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 2015 65 187 192. doi: 10.1161/HYPERTENSIONAHA.114.04492.
12. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H., Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 6 270 276. doi: 10.1016/j.jash.2012.04.004.
13. ESH/ESC Task Force for the Management of Arterial Hypertension 2013 practice guidelines for the management of arterial hypertension of the european society of hypertension (ESH) and the european society of cardiology (ESC). J Hypertens 2013 31 1925 1938
14. Hathout GM, Fink JR, El-Saden SM, Grant EG., Sonographic NASCET index: a new doppler parameter for assessment of internal carotid artery stenosis. AJNR Am J Neuroradiol 2005 26 68 75
15. Wallbach M, Lehnig LY, Helms HJ, Schroer C, Müller GA, Wachter R, Koziolek MJ., Long-Term effects of baroreflex activation therapy on glucose metabolism. Acta Diabetol 2015 52 829 835. doi: 10.1007/s00592-014-0679-7.
16. Wallbach M, Lehnig LY, Schroer C, Hasenfuss G, Müller GA, Wachter R, Koziolek MJ., Impact of baroreflex activation therapy on renal function-A pilot study. Am J Nephrol 2014 40 371 380. doi: 10.1159/000368723.
17. Wallbach M, Lehnig LY, Schroer C, Helms HJ, Lüders S, Patschan D, Patschan S, Müller GA, Wachter R, Koziolek MJ., Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Hypertens 2015 33 181 186. doi: 10.1097/HJH.0000000000000361.
18. Friede T, Kieser M., Sample size recalculation in internal pilot study designs: a review. Biom J 2006 48 537 555
19. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD., Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-Term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012 6 152 158. doi: 10.1016/j.jash.2012.01.003.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 1206 1252. doi: 10.1161/01.HYP.0000107251.49515.c2.
21. Mancia G, Fagard R, Narkiewicz K, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013 34 2159 2219. doi: 10.1093/eurheartj/eht151.
22. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC., Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015 3 487 496. doi: 10.1016/j.jchf.2015.02.006.
23. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H., Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 6 270 276. doi: 10.1016/j.jash.2012.04.004.
24. Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM., Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension 2014 64 281 286. doi: 10.1161/HYPERTENSIONAHA.114.03292.
25. De la Sierra A., Advantages of ambulatory blood pressure monitoring in assessing the efficacy of antihypertensive therapy. Cardiol Ther 2015 4 5 17
26. Pickering TG, Shimbo D, Haas D., Ambulatory blood-pressure monitoring. N Engl J Med 2006 354 2368 2374. doi: 10.1056/NEJMra060433.
27. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, Kieval RS., Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 2007 49 373 379. doi: 10.1161/01.HYP.0000253507.56499.bb.
28. Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG., Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-Analysis. Hypertension 2008 52 856 864. doi: 10.1161/HYPERTENSIONAHA.108.115600.
29. Mancia G, Parati G., Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-Analysis. J Hypertens 2004 22 435 445
30. Schmieder RE, Schmidt ST, Riemer T, Dechend R, Hagedorn I, Senges J, Messerli FH, Zeymer U., Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension 2014 64 1067 1072. doi: 10.1161/HYPERTENSIONAHA.113.03140.
31. Howard JP, Nowbar AN, Francis DP., Size of blood pressure reduction from renal denervation: insights from meta-Analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013 99 1579 1587. doi: 10.1136/heartjnl-2013-304238.
32. Møller DS, Dideriksen A, Sørensen S, Madsen LD, Pedersen EB., Accuracy of telemedical home blood pressure measurement in the diagnosis of hypertension. J Hum Hypertens 2003 17 549 554. doi: 10.1038/sj.jhh.1001584.
33. Mahfoud F, Ukena C, Schmieder RE, Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013 128 132 140. doi: 10.1161/CIRCULATIONAHA.112.000949.
34. de Leeuw PW, Bakris GL, Nadim MK, Haller H, Lovett EG, Bisognano JD., 8B.06: Baroreflex activation therapy consistently maintains blood pressure reduction in a large resistant hypertension cohort for at least 6 years. J Hypertens 2015 33 suppl 1 e108. doi: 10.1097/01.hjh.0000467642.47246.de.
35. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 1903 1913
36. Sayk F, Becker C, Teckentrup C, Fehm HL, Struck J, Wellhoener JP, Dodt C., To dip or not to dip: on the physiology of blood pressure decrease during nocturnal sleep in healthy humans. Hypertension 2007 49 1070 1076. doi: 10.1161/HYPERTENSIONAHA.106.084343.
37. Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E, ASCOT Investigators Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-An Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009 27 876 885. doi: 10.1097/HJH.0b013e328322cd62.
38. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E., Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005 46 156 161. doi: 10.1161/01.HYP.0000170138.56903.7a.
39. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, Mancia G., Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens 1998 16 733 738
40. Fedecostante M, Barbatelli P, Guerra F, Espinosa E, Dessì-Fulgheri P, Sarzani R., Summer does not always mean lower: seasonality of 24 h, daytime, and night-Time blood pressure. J Hypertens 2012 30 1392 1398. doi: 10.1097/HJH.0b013e328354668a.
41. Lambert T, Blessberger H, Gammer V, Nahler A, Grund M, Kerschner K, Buchmayr G, Saleh K, Kammler J, Steinwender C., Effects of renal denervation on ambulatory blood pressure measurements in patients with resistant arterial hypertension. Clin Cardiol 2014 37 307 311. doi: 10.1002/clc.22269.
42. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE., Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol 2013 62 1880 1886. doi: 10.1016/j.jacc.2013.06.023.
43. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 370 1393 1401. doi: 10.1056/NEJMoa1402670.
44. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW., Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013 31 766 774. doi: 10.1097/HJH.0b013e32835e2286.